VZV in the Enteric Nervous System: Pathogenesis and Consequences

NCT IDNCT05550194ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 4

Target enrollment

Study length

about 3.4 years

Ages

18–75

Locations

1 site in TN

What this study is about

This trial is testing whether eradicating varicella-zoster virus (VZV) can improve achalasia, a condition where food cannot pass from the esophagus to stomach. The goal is to understand how VZV affects the digestive system and identify genetic factors involved in its reactivation.

Simplified from trial records by PatientMatch.

What you may be asked to do

1.Receive Shingrix
2.Take ValACYclovir 1000 MG

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Oral

How treatment is administered

Treatment Assignment

All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

vaccine (Recombinant zoster vaccine; evokes immunity to varicella-zoster virus), valaciclovir (Antiviral; prodrug of acyclovir)

Drug routes

oral (Oral Tablet)

Screen for this study View on ClinicalTrials.gov